Skip to main content
Premium Trial:

Request an Annual Quote

TherImmune Acquisition Helps Buoy Gene Logic Q4 Revenue

NEW YORK, Feb. 20 (GenomeWeb News) - Gene Logic reported an increase in total fourth-quarter revenue, but if the company hadn't acquired TherImmune Research, its revenues would have fallen around $1 million.

 

Revenues for the three months ended Dec. 31 increased to $19.7 million from $14.8 million one year ago largely on the shoulders of the $5.8 million generated by TherImmune Research, which Gene Logic acquired last April. Without the acquiaition, Gene Logic's revenue for the fourth quarter 2003 would have been $13.9 million compared with $14.8 million for the same period one year ago.

 

R&D costs decreased to $500,000 from $800,000 during the same quarter a year ago, while net loss decreased to $4.9 million, or $.16 per share, from $5.2 million, or $.19 per share, during the fourth quarter a year ago.

 

As of Dec. 31, Gene Logic had approximately $111.8 million in cash, cash equivalents and marketable securities available-for-sale. This includes $48.7 million in cash and cash equivalents.

 

Click here for the full earnings report.

 

Separately, Gene Logic said that Boehringer Ingelheim has renewed its license to Gene Logic's GeneExpress information services for several years.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.